Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127139791 | 12713979 | 1 | I | 20160829 | 20160905 | 20160905 | EXP | IT-ROCHE-1822650 | ROCHE | CAMERINI A, CHELLA A, MAZZONI F, PUCCETTI C, DONATI S, LUNGHI A, PETRENI P, TARTARELLI G, SERRADORI M, DI COSTANZO F AND AMOROSO D FIRST-LINE TREATMENT OF NSCLC WITH BEVACIZUMAB: REAL WORLD DATA FROM AN ITALIAN REGIONAL BASED SURVEY . JOURNAL OF CHEMOTHERAPY 2016 AUG 13;:1-4. | 0.00 | Y | 0.00000 | 20160905 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127139791 | 12713979 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 7.5 | MG/KG | SOLUTION FOR INFUSION | Q3W | ||||||
| 127139791 | 12713979 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | Q3W | ||||||
| 127139791 | 12713979 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 75 MG/SQ | U | 0 | Q3W | ||||||||
| 127139791 | 12713979 | 4 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 1250 MG/SQ | U | 0 | |||||||||
| 127139791 | 12713979 | 5 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC 5 | U | 0 | Q3W | ||||||||
| 127139791 | 12713979 | 6 | SS | PACLITAXEL. | PACLITAXEL | 1 | Intravenous (not otherwise specified) | 175 MG/SQ | U | 0 | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127139791 | 12713979 | 1 | Non-small cell lung cancer |
| 127139791 | 12713979 | 3 | Non-small cell lung cancer |
| 127139791 | 12713979 | 4 | Non-small cell lung cancer |
| 127139791 | 12713979 | 5 | Non-small cell lung cancer |
| 127139791 | 12713979 | 6 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127139791 | 12713979 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127139791 | 12713979 | Acute myocardial infarction | |
| 127139791 | 12713979 | Anaemia | |
| 127139791 | 12713979 | Blood pressure increased | |
| 127139791 | 12713979 | Deep vein thrombosis | |
| 127139791 | 12713979 | Diarrhoea | |
| 127139791 | 12713979 | Fatigue | |
| 127139791 | 12713979 | Haemoptysis | |
| 127139791 | 12713979 | Intestinal haemorrhage | |
| 127139791 | 12713979 | Intestinal perforation | |
| 127139791 | 12713979 | Ischaemic stroke | |
| 127139791 | 12713979 | Leukopenia | |
| 127139791 | 12713979 | Mucosal inflammation | |
| 127139791 | 12713979 | Nausea | |
| 127139791 | 12713979 | Neutropenia | |
| 127139791 | 12713979 | Peripheral sensory neuropathy | |
| 127139791 | 12713979 | Pulmonary embolism | |
| 127139791 | 12713979 | Thrombocytopenia | |
| 127139791 | 12713979 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |